Synaptogenix acquires significant stake in cannasoul analtyics ltd. co-founded by the technion - israel institute of technology

Acquires 25% stake in cannasoul analytics for up to $4 million to support r&d for cannabinoid- and psilocybin mushroom-based therapeutics for multiple indications partners to drive development and commercialization of cannasoul analytics' intellectual property and technologies licensed from the technion - israel institute of technology new york , nov. 2, 2023 /prnewswire/ -- synaptogenix, inc. (nasdaq: snpx) ("synaptogenix" or the "company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced a new partnership with cannasoul analytics ltd. ("cannasoul") in support of research and development of pharmaceutical therapeutics.
SNPX Ratings Summary
SNPX Quant Ranking